Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0QNF4)

Drug Name

TRx0237 Drug Info

Synonyms

951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 3	[1]

Cross-matching ID

PubChem CID: 23651551
CAS Number: CAS 951131-15-0
TTD Drug ID: DM0QNF4

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[3]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[4]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[5]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[6]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[7]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[4]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[7]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[8]
Bepranemab	DMRQIJO	Alzheimer disease	8A20	Phase 2	[9]
JNJ-63733657	DMMKWGJ	Alzheimer disease	8A20	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
3	Clinical pipeline report, company report or official report of TauRx.
4	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
5	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
6	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
9	Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
10	ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.